Einträge von Tabatabai, Ghazaleh auf dem Publikationsserver

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael , Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias , Schuss, Patrick , Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank , Herrlinger, Ulrich und Schneider, Matthias (2022) Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. Trials 23 (1). Volltext nicht vorhanden.

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Weller, Johannes , Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert , Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich und Schäfer, Niklas (2019) Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 20 (10), S. 1444-1453. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter , Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin und Herrlinger, Ulrich (2017) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology 20 (7), S. 975-985. Volltext nicht vorhanden.

Suchorska, Bogdana, Weller, Michael, Tabatabai, Ghazaleh, Senft, Christian , Hau, Peter, Sabel, Michael C., Herrlinger, Ulrich, Ketter, Ralf, Schlegel, Uwe, Marosi, Christine, Reifenberger, Guido, Wick, Wolfgang, Tonn, Jörg C. und Wirsching, Hans-Georg (2016) Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. Neuro-Oncology 18 (4), S. 549-556. Volltext nicht vorhanden.

Wick, Wolfgang, Platten, Michael, Meisner, Christoph, Felsberg, Jörg, Tabatabai, Ghazaleh, Simon, Matthias, Nikkhah, Guido, Papsdorf, Kirsten, Steinbach, Joachim P., Sabel, Michael, Combs, Stephanie E., Vesper, Jan, Braun, Christian, Meixensberger, Jürgen, Ketter, Ralf, Mayer-Steinacker, Regine, Reifenberger, Guido und Weller, Michael (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. The lancet oncology 13 (7), S. 707-715. Volltext nicht vorhanden.